Abstract
Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia, resulting in increased risk of both microvascular and cardiovascular complications. Traditional treatments for type 2 diabetes have focused on impaired insulin secretion and insulin resistance. These strategies are typically used in a stepwise manner: employing oral glucose lowering agents, followed by insulin therapy. This traditional approach fails to address the progressive decline in β-cell function. Moreover, these therapies are often associated with weight gain in overweight or obese patients with type 2 diabetes. Both exogenous insulin and insulin secretagogues are associated with an increased risk of hypoglycemia. Recently, new treatments that leverage the glucoregulatory effects of incretin hormones, such as glucagon-like peptide-1 have been introduced. Both incretin mimetics and DPP-4 inhibitors address both the underlying pathophysiology and overcome several of the limitations of established therapies by providing improvements in glycemia, and control of body weight with minimal risk of hypoglycemia.
Keywords: Body weight, DPP-4 inhibitor, Glycemia, Incretin mimetic, Type 2 diabetes
Current Diabetes Reviews
Title: Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors
Volume: 4 Issue: 2
Author(s): Anthony Stonehouse, Ted Okerson, David Kendall and David Maggs
Affiliation:
Keywords: Body weight, DPP-4 inhibitor, Glycemia, Incretin mimetic, Type 2 diabetes
Abstract: Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia, resulting in increased risk of both microvascular and cardiovascular complications. Traditional treatments for type 2 diabetes have focused on impaired insulin secretion and insulin resistance. These strategies are typically used in a stepwise manner: employing oral glucose lowering agents, followed by insulin therapy. This traditional approach fails to address the progressive decline in β-cell function. Moreover, these therapies are often associated with weight gain in overweight or obese patients with type 2 diabetes. Both exogenous insulin and insulin secretagogues are associated with an increased risk of hypoglycemia. Recently, new treatments that leverage the glucoregulatory effects of incretin hormones, such as glucagon-like peptide-1 have been introduced. Both incretin mimetics and DPP-4 inhibitors address both the underlying pathophysiology and overcome several of the limitations of established therapies by providing improvements in glycemia, and control of body weight with minimal risk of hypoglycemia.
Export Options
About this article
Cite this article as:
Stonehouse Anthony, Okerson Ted, Kendall David and Maggs David, Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors, Current Diabetes Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339908784220705
DOI https://dx.doi.org/10.2174/157339908784220705 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Extra Virgin Olive Oil and Table Olives on the ImmuneInflammatory Responses: Potential Clinical Applications
Endocrine, Metabolic & Immune Disorders - Drug Targets Association of Low Vitamin D with Complications of HIV and AIDS: A literature Review
Infectious Disorders - Drug Targets Role of the Gut Microbiome in Diabetes and Cardiovascular Diseases Including Restoration and Targeting Approaches- A Review
Drug Metabolism and Bioanalysis Letters Nanotechnology Advanced Strategies for the Management of Diabetes Mellitus
Current Drug Targets The Crosstalk between Gut Inflammation and Gastrointestinal Disorders During Acute Pancreatitis
Current Pharmaceutical Design Overview of Experimental and Conventional Pharmacological Approaches in the Treatment of Sleep and Wake Disorders
Current Topics in Medicinal Chemistry CFTR Inhibitors
Current Pharmaceutical Design Current Status of Molecular Imaging in Inflammatory and Autoimmune Disorders
Current Pharmaceutical Design Recent Advances in Protein Tyrosine Phosphatase Detection Using Chemical Probes
Anti-Cancer Agents in Medicinal Chemistry Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities
Current Topics in Medicinal Chemistry Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Cell Dormancy and Tumor Refractory
Anti-Cancer Agents in Medicinal Chemistry Dampening the Progression of Dementia
Current Neurovascular Research The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials
Current Diabetes Reviews PPAR-γ and Wnt Regulate the Differentiation of MSCs into Adipocytes and Osteoblasts Respectively
Current Stem Cell Research & Therapy Editorial (Hot Topics: New Insights in the Pathogenesis and Treatment of Diabetic Retinopathy)
Current Medicinal Chemistry Targeting PPAR Isoforms Following CNS Injury
Current Drug Targets Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry Sleep and Antidepressant Treatment
Current Pharmaceutical Design Expression, Purification and Characterization of Recombinant Canine FGF21 in Escherichia coli
Protein & Peptide Letters